Cooperative Agreement 2605008
Award Date 8/1/26
Completion Date 7/31/28
Dollars Obligated $1.3M
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
San Francisco, CA 94107, USA
Similar Awards
- This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to Om Therapeutics Inc. will support the development of a system to enable the rapid, scalable, and cost-effective discovery of new medicines using machine learning. The project aims to encapsulate proteins and small molecules in millions of miniaturized compartments to screen for interactions that could identify novel drug candidates. The key innovations include...
- The National Science Foundation awarded a $1.25 million Cooperative Agreement to Cerflux Inc. on August 1, 2026, under the SBIR Phase II program (CFDA 47.084, NSF Technology, Innovation, and Partnerships). Cerflux will develop a scalable ex vivo testing platform built on three-dimensional tissue engineering to screen anticancer agents against solid tumors. The platform recreates key structural and biological features of tumor tissue outside the body for quantitative drug response testing....
- The National Science Foundation awarded Spectral Therapeutics, Inc. $304,950 on July 1, 2026, under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to develop a novel platform for quantitative activity screening of chemical compound libraries using spectrally-encoded laser particles. The recipient will integrate III-V semiconductor laser particles as narrow-emission spectral barcodes into polymer beads and screen them in high-density microwell arrays to enable over one...
- Federal Cooperative Agreement Summary Opera Bioscience, Inc., a woman-owned small business located in Evanston, Illinois, received a Cooperative Agreement award of $1,248,994 from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) on June 15, 2025. The award supports Phase II development of an innovative gram-negative bacterial protein secretion platform designed to enable cost-effective, high-purity recombinant protein production...
- The U.S. National Science Foundation (NSF) awarded a $303,864 Phase I Small Business Innovation Research (SBIR) grant under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program to Core Biotherapeutics, Inc. (UEI N9FGZ15RQGJ4) located in Ladera Ranch, CA. The project aims to develop a platform for discovering therapeutic drug candidates that can modulate molecular networks driving diseases, with the potential to produce disease-modifying effects for neurodegenerative...
- Award Summary Orion Therapeutics Inc. received a $1.25M Small Business Technology Transfer (STTR) Phase II Cooperative Agreement from the National Science Foundation (NSF) Technology, Innovation, and Partnerships program (CFDA 47.084), awarded September 15, 2025, with completion targeted for August 31, 2027. The project focuses on developing and advancing a multifunctional lipid nanoparticle (LNP) delivery platform designed to enable safe and targeted delivery of RNA therapeutics to specific...
- Federal Cooperative Agreement Summary Pumpkinseed Technologies Inc. received a $1.249 million Small Business Innovation Research (SBIR) Phase II Cooperative Agreement from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) for the period August 1, 2025 through July 31, 2027. The award funds the development of a high-throughput de-novo peptide sequencing technology utilizing metasurface optics to identify and characterize...
- This SBIR Phase I award from the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $273,550 to Biocognon LLC for the development of a combinatorial platform to discover improved molecular recognition components for use in therapeutic and diagnostic antibodies. The project aims to utilize synthetic biology, next-generation DNA sequencing, and computational biology to efficiently generate and screen libraries of antibody...
- The National Science Foundation awarded a $275,000 Project Grant to Oraliva, Inc. under the Technology, Innovation, and Partnerships program to develop a portable, programmable single cell cytology platform for the early detection of epithelial cancers. The platform will combine microfluidics and artificial intelligence to classify potentially cancerous tissue in near real-time through multiparameter single-cell analysis and automated evaluation. The objectives are to link different clinical...
- The National Science Foundation awarded Noara Therapeutics Corp. $305,000 on July 1, 2026, under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to develop design strategies that improve the efficacy, durability, and safety of RNA-based therapeutics. This Small Business Innovation Research Phase I project addresses the technical barrier that chemical modifications to RNA molecules, while enhancing stability and safety, can interfere with essential molecular functions and...